Clinical Trials
4 trialsNCT04975555 2026-06-03
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
University of Alabama at Birmingham
Phase 2 Completed
NCT06447376 2025-05-11
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
Case Comprehensive Cancer Center
Phase 1 Recruiting
NCT05665725 2025-01-31
Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02805868 2016-10-24
Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
Northwestern University
Phase EARLY_PHASE1 Withdrawn